Core Viewpoint - Tonghua Dongbao (600867.SH) has announced a change in its financial report and internal control audit institution for the year 2025 to Daixin Certified Public Accountants (Special General Partnership), with an audit fee of 1.5 million yuan [1] Group 1 - The change is based on business development and future audit needs, following careful evaluation and competitive negotiation [1] - The company has communicated sufficiently with the previous auditor, Beijing Dehao International Accounting Firm (Special General Partnership), which has no objections to the change [1] Group 2 - This marks the third consecutive year that Tonghua Dongbao has changed its annual audit institution [1] - The audit institution for 2023 was Zhongzhun Certified Public Accountants, which had served for 30 years; in 2024, the company switched to Beijing Dehao International Accounting Firm, and now it plans to change again [1]

Core Insights - The biopharmaceutical sector experienced a slight increase of 0.14% on October 20, with Iwu Biologics leading the gains [1] - The Shanghai Composite Index closed at 3863.89, up 0.63%, while the Shenzhen Component Index closed at 12813.21, up 0.98% [1] Biopharmaceutical Sector Performance - Iwu Biologics (300357) saw a significant rise of 10.07%, closing at 32.90 with a trading volume of 228,200 shares and a transaction value of 737 million [1] - Other notable gainers included Olin Biologics (6168889) with a 4.58% increase, closing at 23.96, and Kangchen Pharmaceutical (603590) with a 4.00% increase, closing at 51.19 [1] - The sector also had some underperformers, such as Novavax (688105) which fell by 3.56%, closing at 21.96 [2] Capital Flow Analysis - The biopharmaceutical sector experienced a net outflow of 239 million from institutional investors, while retail investors saw a net inflow of 270 million [2] - The data indicates that retail investors are actively buying into the sector despite the overall net outflow from larger institutional players [2] Individual Stock Capital Flow - Iwu Biologics had a net inflow of 23.19 million from institutional investors, while it faced a net outflow of 17.27 million from speculative funds [3] - Notably, Huashan Biologics (002007) had a net inflow of 42.16 million from institutional investors, indicating strong institutional interest [3]

Investment Rating - The report maintains a "Positive" investment rating for the insulin industry [10] Core Insights - The insulin market is stabilizing post-collection procurement, with companies focusing on innovation and steady progress in R&D pipelines, creating a closed-loop advantage in insulin, diabetes, endocrine, and metabolism sectors [3][9] - The progress of insulin exports is promising, expected to contribute to new growth [8] - The cash flow of companies is gradually stabilizing, and the valuation of innovative pipelines is likely to be reshaped [9] Summary by Sections Domestic Insulin Collection Procurement - The domestic insulin market is broad, with insulin analogs becoming the main driving force. In 2021, there were approximately 14.1 million diabetes patients in China, with an expected increase to 29.3 million by 2030. The market size for insulin in China is projected to be 22.3 billion yuan in 2024, reflecting a year-on-year decrease of 14.23% [20] - The first round of national collection procurement was moderate, ensuring basic procurement volume and expanding external market channels. Nearly 50% of the insulin market share was not included in the procurement, allowing leading companies to significantly increase sales volume [27][20] - The second round of procurement renewal has seen price increases for some companies, reflecting a balanced approach by the National Medical Insurance Administration [30][27] Insulin Export Progress - Companies like Ganli Pharmaceutical and Tonghua Dongbao are making significant progress in exporting insulin to developed regions like Europe and the US, where the insulin market is valued at $13.2 billion. The market in developing regions such as Asia, Africa, and Latin America is estimated to be between $4.3 billion and $6.5 billion [8][20] Innovative Drug Pipeline - The innovative drug pipeline is gradually yielding results, with a focus on GLP-1 research and development. Insulin companies are expected to leverage their advantages in sales terminals, process development, and production capacity in the GLP-1 sector [9][8] - The management teams and innovation systems of these companies are undergoing significant changes, which may lead to a reshaping of their valuations [9]

Major Announcements - Jinling Mining has decided to suspend the public transfer of 100% equity and debt of JG Mining due to the lack of qualified buyers during the second public listing phase [4] - Huibo Yuntong's controlling shareholder and actual controller have voluntarily committed not to reduce their holdings of the company's stock during a specific period, coinciding with the planned acquisition of Baode Computer Systems [5] - Weigao Blood Purification is planning to purchase 100% equity of Weigao Purui through a share issuance, with trading expected to be suspended from October 20, 2025 [6] - Ganfeng Lithium intends to transfer part of its equity in Shenzhen Yichu to introduce a strategic investor for 664 million yuan, which will result in Shenzhen Yichu no longer being included in the consolidated financial statements [7] - Sanhua Intelligent Control has raised the upper limit for its share repurchase price from 35.75 yuan to 60.00 yuan and extended the implementation period by two months [8] - Jingwei Huikai plans to acquire 100% equity of ZTE Systems for 850 million yuan, entering the private network communication sector [9] Performance Reports - Cambrian reported a third-quarter net profit of 567 million yuan, with a revenue increase of 1332.52% year-on-year [10] - Hikvision's third-quarter net profit grew by 20.31%, with revenues of 239.4 billion yuan [12] - Kewell's third-quarter net profit increased by 110.36%, with revenues of 14.5 million yuan [13] - Siwei Technology expects a net profit increase of 140% to 169% for the first three quarters, driven by strong smartphone sector performance [14] - Shentong Technology's third-quarter net profit surged by 452.62%, with revenues of 4.86 billion yuan [15] - Huayou Cobalt's net profit for the first three quarters increased by 39.59%, benefiting from integrated operations and rising cobalt prices [16] - Shenghui Integration reported a third-quarter net profit growth of 93.89% [17] - Jinshi Yaya expects a net profit increase of 48.99% to 83.95% for the first three quarters due to successful commercialization of R&D projects [18] - Haida Group's net profit for the first three quarters grew by 14.31%, and the company plans to spin off its subsidiary for a Hong Kong listing [19] - Hanlan Environment anticipates a net profit increase of approximately 15.85% for the first three quarters [20] - Haitong Development's net profit for the first three quarters decreased by 38.47% due to market price declines and rising operational costs [21] - Explorer expects a net profit decline of 64.62% to 70.51% for the first three quarters due to poor sales in outdoor business [22] - Guoji General's net profit for the third quarter decreased by 46.73% due to a decline in project revenue recognition [23] Major Contracts - Xinjiang Jiaojian has been awarded a construction project worth 556 million yuan [24] - Robotech signed a contract worth approximately 761 million yuan, representing about 68.83% of its 2024 revenue [25] - Shengshi Technology signed a contract for the Hunchun Port project worth 102 million yuan [26] Shareholding Changes - Youfa Group's director plans to reduce his holdings by up to 3.54 million shares [27] - Shengbang shares' controlling shareholder plans to reduce holdings by up to 1.28% [28] - Hunan Silver's major shareholder plans to reduce holdings by up to 2% [29] Share Buybacks - Tonghua Dongbao plans to repurchase shares worth 20 million to 40 million yuan [30] - Shenzhen New Star intends to raise its share repurchase price limit from 18 yuan to 30 yuan [31] Financing Activities - Changsha Bank has received approval to issue capital instruments not exceeding 12 billion yuan [32]

（文章来源：证券日报） 证券日报网讯 10月17日晚间，通化东宝发布公告称，公司拟使用自有资金通过上海证券交易所交易系 统以集中竞价交易方式回购公司股份，用于员工持股计划及/或股权激励。回购股份金额不低于人民币 2，000万元（含），不超过人民币4，000万元（含）；回购股份价格：不超过人民币10元/股（含）； 该回购股份价格上限不高于董事会审议通过本次回购股份方案前30个交易日公司股票交易均价的 150%。 ...

Core Viewpoint - Tonghua Dongbao (600867) announced a share buyback plan using its own funds, with a total amount between 20 million yuan and 40 million yuan, aimed at employee stock ownership plans and/or equity incentives [1] Group 1: Buyback Details - The company plans to repurchase shares with a minimum amount of 20 million yuan and a maximum of 40 million yuan [1] - The buyback is intended to enhance the company's market image and boost investor confidence [1] Group 2: Rationale Behind the Buyback - The decision is based on the company's confidence in its future development prospects and high recognition of its value [1] - The company considered its recent stock market performance, operational conditions, main business development prospects, financial status, and future profitability when making this decision [1]

Performance - Cambrian's Q3 revenue reached 1.727 billion yuan, a year-on-year increase of 1332.52%; net profit was 567 million yuan [1] - Hikvision's Q3 net profit grew by 20.31% year-on-year [5] - Sitaiwei's net profit for the first three quarters is expected to increase by 140% to 169% year-on-year [5] - Northern Heavy Industries anticipates a year-on-year net profit increase of 56.90% to 70.74% for the first three quarters [5] - Jintian's net profit for the first three quarters increased by 104.37% year-on-year [5] - Yingshi Network's Q3 net profit grew by 28.73% year-on-year [5] - Sankeshu's net profit for the first three quarters increased by 81.22% year-on-year, with a proposed dividend of 5 yuan per 10 shares [5] - Pianzaihuang's Q3 net profit decreased by 28.82% year-on-year [5] - Shentong Technology's Q3 net profit surged by 452.62% year-on-year [5] - Huayou Cobalt's net profit for the first three quarters increased by 39.59% year-on-year [5] - Guotou Power's Q3 power generation reached 47.891 billion kWh, a year-on-year decrease of 14.42% [5] - Rongbai Technology reported a Q3 net loss of 135 million yuan [5] - Zijin Mining's Q3 net profit increased by 52.25% year-on-year [5] - Haida Group's net profit for the first three quarters increased by 14.31%, planning to spin off its subsidiary Haida Holdings for a Hong Kong listing [5] Share Buybacks and Reductions - Fujirui plans to repurchase shares worth 10 million to 20 million yuan [3] - Tonghua Dongbao intends to repurchase shares worth 20 million to 40 million yuan [3] - Shenzhen New Star plans to adjust the maximum repurchase price to no more than 30 yuan per share [3] - Sanhua Intelligent Control has raised the maximum repurchase price and extended the implementation period [3] - Dayang Electric has also raised the maximum repurchase price and extended the implementation period [3] - Hunan Baiyin's controlling shareholder plans to reduce its stake by no more than 2% [5] - Shengbang shares' controlling shareholder plans to reduce its stake by no more than 1.28% [5] - Liandong Technology's actual controller plans to reduce its stake by no more than 2.9963% [5] - Juxing Agriculture's shareholder plans to reduce its stake by no more than 2% [5] - Aerospace Engineering's shareholders plan to reduce their stakes by no more than 6% [5] Contracts and Collaborations - Yongmaotai signed a strategic cooperation framework agreement with a leading humanoid robot company [3] - Xinjiang Jiaojian won a construction project worth 556 million yuan [4] - Jingjiawei signed a strategic cooperation agreement with Cangqiong Digital to create a fully domestic integrated solution [3] - Shengshi Technology signed a contract for a project worth 102 million yuan at Hunchun Port [3] - Robotech signed a contract worth approximately 761 million yuan, accounting for about 68.83% of the company's 2024 revenue [3] - Guangdong Construction's subsidiary signed a cooperation framework agreement with the Maoming Binhai New Area Management Committee [3] Mergers and Acquisitions - Jingwei Huikai plans to acquire 100% of Zhongxing System for 850 million yuan, entering the private network communication field [6] - Weigao Blood Purification intends to purchase 100% of Weigao Purui's shares, with stock trading suspended from October 20 [6] - GoerTek terminated its planned acquisition of Mia Precision Technology and Changhong Industrial [6] Financing - Changsha Bank received regulatory approval to issue capital instruments not exceeding 12 billion yuan [6]

通化东宝药业股份有限公司 关联交易管理制度 第二章 关联人和关联交易的范围 第一章 总 则 第一条 为规范通化东宝药业股份有限公司(以下简称"公司")关联交易， 维护公司股东特别是中小股东的合法权益，确保公司签订的关联交易合同符合 公平、公正、公开的原则，根据《公司法》《证券法》《上市公司信息披露管理办法》 《上海证券交易所上市公司自律监管指引第5号--交易与关联交易》《上海证券交易 所股票上市规则》及其他有关法律法规、规范性文件及公司章程的规定，制定本制 度。 第二条 公司的关联交易是指公司、控股子公司及控制的其他主体与公司 关联人之间发生的转移资源或者义务的事项。 第三条 公司的关联交易应当遵循以下基本原则： （一）平等、自愿、等价、有偿的原则； （二）公平、公正、公开的原则； （三）关联方如在股东会上享有表决权，除特殊情形外，均应对关联交易事 项回避表决； （四）与关联方有任何利害关系的董事，在董事会就该关联交易事项进行 表决时，应当回避； （五）公司董事会应当根据客观标准判断该关联交易是否对公司有利，必 要时应聘请专业评估机构或独立财务顾问发表意见。 第四条 公司的关联人包括关联法人（或者其他组织）和 ...

通化东宝药业股份有限公司 股东会议事规则 第一章 总 则 第一条 为规范通化东宝药业股份有限公司(以下简称"公司")的组织和行 为，保证股东会依法行使职权，根据《公司法》《证券法》《上市公司股东会规 则》《上海证券交易所股票上市规则》《上海证券交易所上市公司自律监管指引 第 1 号——规范运作》等有关法律法规和规范性文件以及公司章程的有关规定， 结合公司实际情况，制定本规则。 第二条 公司应当严格按照法律、行政法规、本规则及公司章程的相关规定 召开股东会，保证股东能够依法行使权利。 公司董事会应当切实履行职责，认真、按时组织股东会。公司全体董事应当 勤勉尽责，确保股东会正常召开和依法行使职权。 第三条 股东会是公司的权力机构,依法行使下列职权： （一）选举和更换董事，决定有关董事的报酬事项； （二）审议批准董事会的报告； （三）审议批准公司的利润分配方案和弥补亏损方案； （四）对公司增加或者减少注册资本作出决议； （五）对发行公司债券作出决议； （六）对公司合并、分立、解散、清算或者变更公司形式作出决议； （七）修改公司章程； （八）对公司聘用、解聘承办公司审计业务的会计师事务所作出决议； （九）审议批准本规 ...

通化东宝药业股份有限公司 对外担保管理制度 第一章 总 则 第一条 为维护投资者的利益，规范通化东宝药业股份有限公司（以下简称"公 司"）的对外担保行为，有效控制公司对外担保风险，确保公司资产安全，促进公司健 康稳定地发展，根据《公司法》《证券法》《上市公司监管指引第8号——上市公司 资金往来、对外担保的监管要求》《上海证券交易所股票上市规则》等法律法规以 及公司章程的有关规定，制定本制度。 第二条 本制度所称对外担保是指公司为他人提供的担保，包括公司对控股子 公司的担保。 第三条 公司控股子公司对于向公司合并报表范围之外的主体提供担保的，应 视同公司提供担保，公司应按照本制度规定执行。 第四条 公司对外担保应遵循平等、自愿、诚信、互利的原则，拒绝强令为他 人担保的行为。 第五条 公司对外担保实行统一管理，公司的分支机构不得对外提供担保。未 经董事会或者股东会审议通过，公司不得对外提供担保。 第六条 董事会应审慎对待和严格控制对外担保产生的或有债务风险，并对违 规或失当的担保产生的损失依法承担连带责任。 第二章 担保条件 第七条 公司可以为具有独立法人资格且具备下列条件之一的单位提供担保： （1）因公司业务需 ...